medigraphic.com
Revista Latinoamericana de Microbiología

2003, Número 1-2

<< Anterior Siguiente >>

Microbiología 2003; 45 (1-2)


Quimiotaxis de leucocitos humanos y de rata por el opioide no-peptídico, delta-selectivo SNC 80

Ordaz-Sánchez I, Weber RJ, Rice KC, Zhang X, Padilla RC, Tamez-Guerra R, Méndez-Vázquez JL, Gómez-Flores R

Idioma: Ingles.
Referencias bibliográficas: 49
Paginas: 16-23
Archivo PDF: 91.55 Kb.


RESUMEN

Opioides como la morfina, representan la principal fuente de alivio para la mayor parte de los casos de dolor crónico no maligno, moderado o severo. Sin embargo, el abuso de opioides puede llevar a padecer de infecciones tales como la hepatitis y el SIDA, debido a que estas sustancias se han asociado con la supresión de varios parámetros de función inmune incluyendo a la resistencia antimicrobiana, la producción de anticuerpos, la fagocitosis mediada por monocitos/macrófagos, y la quimiotaxis de neutrófilos y monocitos. Nosotros hemos reportado previamente las propiedades inmunopotenciadoras de agonistas y antagonistas selectivos de receptores de opioides no peptídicos. En el presente estudio, se evaluaron los efectos del agonista opioide no peptídico del tipo delta (+)-4-((alfa R)-alfa-((2S, 5R)-4-alil-2, 5-dimetil-1-piperazinil)-3-metoxibenzil)-N, N-dietil-benzamiae (SNC 80) en la quimiotaxis de linfocitos tímicos de rata y de células mononucleares de sangre periférica humana, utilizando una cámara de Wilkinson modificada. Se observó que el SNC 80 a las concentraciones de 10-10,10-9,10-8,10-7, y 10-6 M, estimuló significativamente (p ‹ 0.01) la quimiotaxis (demostrado mediante pruebas de tablero) de linfocitos tímicos de rata (1.3,1.55,1.58,1.75, y 1.8 veces de incremento respectivamente) y leucocitos humanos (1.13,1.37,1.43,1.7, y 1.83 veces de incremento respectivamente) comparado con el control sin tratar. Los efectos del SNC 80 sobre la quimiotaxis de leucocitos de rata y humanos se antagonizaron con el uso de naloxona, indicando que la modulación de la quimiotaxis inducida por este opioide es a través de un receptor clásico de opioides. El desarrollo y uso de opioides no peptídicos como el SNC 80 podrían tener un impacto inmediato no sólo como analgésicos potentes, sino en inmunorregulación.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ader, R., N. Cohen & D.L. Felten. 1985. Brain, behavior, and immunity. Brain Behav. Immun. 1:1-6.

  2. Arora, P.K., E. Fride, J. Petitto, K. Waggie & P. Skolnick. 1990. Morphine-induced immune alterations in vivo. Cell Immunol. 126: 343-353.

  3. Bilsky, E.J., S.N. Calderon, T. Wang, R.N. Bernstein, P. Davis, V.J. Hruby, R.W. McNutt, R.B. Rothman, K.C. Rice & F. Porreca. 1995. SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist. J. Pharmacol. Exp. Ther. 273:359-366.

  4. Calderon, S.N., R.B. Rothman, F. Porreca, J.L. Flippen-Anderson, R.W. McNutt, H. Xu, L.E. Smith, E.J. Bilsky, P. Davis & K.C. Rice. 1994. Probes for narcotic receptor mediated phenomena. 19. Synthesis of (+)-4-[(alphaR)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80): a highly selective, nonpeptide delta opioid receptor agonist. J. Med. Chem. 37:2125-8.

  5. Chen, T., E. Scott & D.C. Morrison. 1994. Differential effects of serum on lipopolysaccharide receptor-directed macrophage activation for nitric oxide production. Immunol. Lett. 40:179-87.

  6. Choi Y., L.F. Chuang, K.M. Lam, H.F. Kung, J.M. Wang, B.I. Osburn & R.Y. Chuang. 1999. Inhibition of chemokine-induced chemotaxis of monkey leukocytes by mu-opioid receptor agonists. In Vivo. 13:389-96.

  7. Chung, C.Y., S. Funamoto & R.A. Firtel. 2001. Signaling pathways controlling cell polarity and chemotaxis. Trends Bioch. Sci. 26:557-66.

  8. Gomez-Flores R., C. Rodríguez-Padilla & R. Tamez-Guerra. 1990. Early production of a chemotactic factor to T lymphocytes by peritoneal macrophages. Cell. Immunol. 126:1-15.

  9. Gómez-Flores, R., S. Gupta, R. Tamez-Guerra & R.T. Mehta. 1995. Determination of MICs for Mycobacterium avium-M. intracellulare complex in liquid medium by a colorimetric method. J. Clin. Microbiol. 33:1842-1846.

  10. Gómez-Flores, R., S. D. Tucker, R. Kansal, R. Tamez-Guerra & R. T. Mehta. 1997. Enhancement of antibacterial activity of clofazimine against Mycobacterium avium-M. intracellulare complex infection induced by IFN-g is mediated by TNF-a. J. Antimicrob. Chemother. 39:189-197.

  11. Gomez-Flores, R. & R.J. Weber. 1999. Opioids, opioid receptors, and the immune system, pp. 281-314. In N. Plotnikoff, R. Faith, A. Murgo and R. Good (Eds). Cytokines-Stress and Immunity. Boca Raton: CRC Press.

  12. Gomez-Flores R. & R.J. Weber. 2001. Increased tumor necrosis factor-a and nitric oxide production by rat macrophages following in vitro stimulation and intravenous administration of the d-opioid agonist SNC 80. Life Sci 68:2675-84.

  13. Grimm, M.C., A. Ben-Baruch, D.D. Taub, O.M. Howard, J.M. Wang & J.J. Oppenheim. 1998. Opiate inhibition of chemokine-induced chemotaxis. Ann. N.Y. Acad. Sci. 840:9-20.

  14. Hambrook, J.M., B.A. Morgan, M.J. Rance & C.F. Smith. 1976. Mode of deactivation of the enkephalins by rat and human plasma and rat brain homogenates. Nature 262:782-783.

  15. Haverkos, H.W. 1987. Factors associated with the pathogenesis of AIDS. J. Infect. Dis. 156:251-7.

  16. Hofbauer, R., D. Moser, H. Salfinger, M. Frass & S. Kapiotis. 1998. Sufentanil inhibits migration of human leukocytes through human endothelial cell monolayers. Anesth. Analg. 87:1181-5.

  17. Hu, S., C.C. Chao, C.C. Hegg, S. Thayer & P.K. Peterson. 2000. Morphine inhibits human microglial cell production of, and migration towards, RANTES. J. Psychopharmacol. 14:238-43.

  18. Ishikawa, M., K. Tanno, A. Kamo, Y. Takayanagi & K. Sasaki. 1993. Enhancement of tumor growth by morphine and its possible mechanism in mice. Biol. Pharmacol. Bull. 16:762-6.

  19. Kaldjian, E.P., G.H. Chen & K.B. Cease. 1992. Enhancement of lymphocyte proliferation assays by use of serum-free medium. J. Immunol. Methods 147:189-95.

  20. Kamada, H., Y. Tsutsumi, Y. Yamamoto, T. Kihira, Y. Kaneda, Y. Mu, H. Kodaira, S.-I. Tsunoda, S. Nakagawa & T. Mayumi. 2000. Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice. Cancer Res. 60:6416-6420.

  21. Kaneider, N.C., C.M. Reinisch, S. Dunzendorfer, J. Romisch & C.J. Wiedermann. 2002. Syndecan-4 mediates antithrombin-induced chemotaxis of human peripheral blood lymphocytes and monocytes. J. Cell Sci. 115:227-36.

  22. Kansal, R., R. Gomez-Flores & R.T. Mehta. 1997. Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex (MAC) in mice depends on size of initial inoculum and duration of infection. Antimicrob. Agents Chemother. 41:17-23.

  23. Kaplan, A.P. 2001. Chemokines, chemokine receptors and allergy. Int. Arch. Allergy Immunol. 124:423-31.

  24. Klimp, A.H., E.G. de Vries, G.L. Scherphof & T. Daemen. 2002. A potential role of macrophage activation in the treatment of cancer. Crit. Rev. Oncol. Hematol. 44:143-161.

  25. Kuijpers, T.W., R.A. Van Lier, D. Hamann, M. de Boer, L.Y. Thung, R.S. Weening, A.J. Verhoeven & D. Roos. 1997. Leukocyte adhesion deficiency type 1 (LAD-1)/variant. A novel immunodeficiency syndrome characterized by dysfunctional beta2 integrins. J. Clin. Investigat. 100:1725-33.

  26. Liu, Y., D.J. Blackbourn, L.F. Chuang, K.F. Killam Jr. & R.Y. Chuang. 1992. Effects of in vivo and in vitro administration of morphine sulfate upon rhesus macaque polymorphonuclear cell phagocytosis and chemotaxis. J. Pharmacol. Exp. Ther. 263:533-9.

  27. Lysle, D.T., M.E. Coussons, V.J. Watts, E.H. Bennett & L.A. Dykstra. 1993. Morphine-induced alterations of immune status: dose dependency, compartment specificity and antagonism by naltrexone. J. Pharmacol. Exp. Ther. 265:1071-1078.

  28. Makman, M.H., T.V. Bilfinger & G.B. Stefano. 1995. Human granulocytes contain an opiate alkaloid-selective receptor mediating inhibition of cytokine-induced activation and chemotaxis. J. Immunol. 154:1323-30.

  29. Matzner, Y. 1987. Neutrophil function studies in clinical medicine. Transf. Med. Rev 1:171-81.

  30. Miyagi, T., L.F. Chuang, K.M. Lam, H. Kung, J.M. Wang, B.I. Osburn & R.Y. Chuang. 2000. Opioids suppress chemokine-mediated migration of monkey neutrophils and monocytes - an instant response. Immunopharmacology 47:53-62.

  31. Negus, S.S., M.B. Gatch, N.K. Mello, X. Zhang & K.C. Rice. 1998. Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in rhesus monkeys. J. Pharmacol. Exp. Ther. 286:362-75.

  32. Ni, X., K.R. Gritman, T.K. Eisenstein, M.W. Adler, K.E. Arfor & R.F. Tuma. 2000. Morphine attenuates leukocyte/endothelial interactions. Microvasc. Res. 60:121-30.

  33. Nowak, J.E., R. Gomez-Flores, S.N. Calderon, K.C. Rice & R.J. Weber. 1998. Rat NK cell, T cell, and macrophage functions following intracerebroventricular injection of SNC 80. J. Pharmacol. Exp. Ther. 286:931-937.

  34. Pacl, D.S. 2001. Managing the pain of advanced chronic disease. Tex. Med. 97:38-41.

  35. Pasnik, J., H. Tchorzewski, Z. Baj, M. Luciak & M. Tchorzewski. 1999. Priming effect of met-enkephalin and beta-endorphin on chemiluminescence, chemotaxis and CD11b molecule expression on human neutrophils in vitro. Immunol. Lett. 67:77-83.

  36. Passik, S.D. & H.J. Weinreb. 2000. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv. Ther. 17:70-83.

  37. Perez-Castrillon, J.L., J.L. Perez-Arellano, J.D. Garcia-Palomo, A. Jimenez-Lopez & S. De Castro. 1992. Opioids depress in vitro human monocyte chemotaxis. Immunopharmacology 23:57-61.

  38. Pitrak, D.L. 1999. Neutrophil deficiency and dysfunction in HIV-infected patients. Am. J. Health Syst. Pharmacol. 56:S9-16.

  39. Rogers, T.J., A.D. Steele, O.M. Howard & J.J. Oppenheim. 2000. Bidirectional heterologous desensitization of opioid and chemokine receptors. Ann. N.Y. Acad. Sci. 917:19-28.

  40. Sharp, B.M., K. McAllen, G. Gekker, N.A. Shahabi & P.K. Peterson. 2001. Immunofluorescence detection of delta opioid receptors (DOR) on human peripheral blood CD4+ T cells and DOR-dependent suppression of HIV-1 expression. J. Immunol. 167:1097-102.

  41. Szabo, I., X.H. Chen, L. Xin, M.W. Adler, O.M. Howard, J.J. Oppenheim & T.J. Rogers. 2002. Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. Proc. Natl. Acad. Sci. U S A. 99:10276-81.

  42. Taub, D.D. & J.J. Oppenheim. 1994. Chemokines, inflammation and the immune system. Ther. Immunol. 1:229-46.

  43. Watson, R.R., R.H. Prabhala, H.R. Darban, M.D. Yahya & T.L. Smith. 1988. Changes in lymphocyte and macrophage subsets due to morphine and ethanol treatment during a retrovirus infection causing murine AIDS. Life Sci. 43: v-xi.

  44. Weber, R.J., L.C. Band, B. de Costa, A. Pert & K.C. Rice. 1991. Neural control of immune function: Opioids, opioid receptors, and immunosuppression. NIDA Res. Monograph Series 105: 96-102.

  45. Wilkinson, P.C. & I.C. McKay. 1971. The chemotactic activity of native and denatured serum albumin. Int. Arch. Allergy Appl. Immunol. 41:237-47.

  46. Wilkinson, C.A. 1975. Leucocyte locomotion and chemotaxis. The influence of divalent cations and cation ionophores. Exp. Cell Res. 93:420-6.

  47. Wilkinson, P.C., M. Komai-Koma & I. Newman. 1997. Locomotion and chemotaxis of lymphocytes. Autoimmunity 26(1):55-72.

  48. Zhang, N., D. Hodge, T.J. Rogers & J.J. Oppenheim. 2003. Ca2+-independent protein kinase Cs mediate heterologous desensitization of leukocyte chemokine receptors by opioid receptors. J. Biol. Chem. 278:12729-12736.

  49. Zigmond, S.H. and J.G. Hirsch. 1973. Leukocyte locomotion and chemotaxis. New method for evaluation, and demonstration of a cell-derived chemotactic factor. J. Exp. Med. 137:387-410.




2020     |     www.medigraphic.com